Co-Diagnostics, Inc. Announces Fourth-Quarter and Full-Year 2020 Earnings Release Date and Webcast
Co-Diagnostics, Inc. (Nasdaq: CODX) will announce its fourth-quarter and full-year 2020 financial results on March 25, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Co-Diagnostics, Inc. (Nasdaq: CODX) will announce its fourth-quarter and full-year 2020 financial results on March 25, 2021, after market close. The company will host a conference call and webcast at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan, CFO Brian Brown, and General Counsel Reed Benson. Investors can access the live event via the company's website. For those unable to attend live, a recording will be made available later.
Details
News Market Reaction – CODX
The recorded move for CODX in the trading session of this news was +0.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, March 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth-quarter and full-year 2020 results on March 25, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. EDT to discuss its financial results with analysts and institutional investors. Management on the call will include CEO Dwight Egan, newly appointed CFO Brian Brown, and Reed Benson, General Counsel.
The call and webcast will be available via:
Webcast: | ir.codiagnostics.com on the Events & Webcasts page |
Conference Call: | 877-317-6789 (domestic) or 412-317-6789 (international) |
If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures, and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
View original content to download multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-fourth-quarter-and-full-year-2020-earnings-release-date-and-webcast-301249972.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.